Literature DB >> 9256490

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

N L Letvin1, D C Montefiori, Y Yasutomi, H C Perry, M E Davies, C Lekutis, M Alroy, D C Freed, C I Lord, L K Handt, M A Liu, J W Shiver.   

Abstract

It is generally thought that an effective vaccine to prevent HIV-1 infection should elicit both strong neutralizing antibody and cytotoxic T lymphocyte responses. We recently demonstrated that potent, boostable, long-lived HIV-1 envelope (Env)-specific cytotoxic T lymphocyte responses can be elicited in rhesus monkeys using plasmid-encoded HIV-1 env DNA as the immunogen. In the present study, we show that the addition of HIV-1 Env protein to this regimen as a boosting immunogen generates a high titer neutralizing antibody response in this nonhuman primate species. Moreover, we demonstrate in a pilot study that immunization with HIV-1 env DNA (multiple doses) followed by a final immunization with HIV-1 env DNA plus HIV-1 Env protein (env gene from HXBc2 clone of HIV IIIB; Env protein from parental HIV IIIB) completely protects monkeys from infection after i.v. challenge with a chimeric virus expressing HIV-1 env (HXBc2) on a simian immmunodeficiency virusmac backbone (SHIV-HXBc2). The potent immunity and protection seen in these pilot experiments suggest that a DNA prime/DNA plus protein boost regimen warrants active investigation as a vaccine strategy to prevent HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256490      PMCID: PMC23198          DOI: 10.1073/pnas.94.17.9378

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Vaccines against human immunodeficiency virus--progress and prospects.

Authors:  N L Letvin
Journal:  N Engl J Med       Date:  1993-11-04       Impact factor: 91.245

2.  HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha.

Authors:  C Lekutis; J W Shiver; M A Liu; N L Letvin
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

3.  Gene inoculation generates immune responses against human immunodeficiency virus type 1.

Authors:  B Wang; K E Ugen; V Srikantan; M G Agadjanyan; K Dang; Y Refaeli; A I Sato; J Boyer; W V Williams; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

4.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.

Authors:  D L Montgomery; J W Shiver; K R Leander; H C Perry; A Friedman; D Martinez; J B Ulmer; J J Donnelly; M A Liu
Journal:  DNA Cell Biol       Date:  1993-11       Impact factor: 3.311

6.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

Authors:  D C Montefiori; W E Robinson; S S Schuffman; W M Mitchell
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

10.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.

Authors:  E F Fynan; R G Webster; D H Fuller; J R Haynes; J C Santoro; H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

View more
  71 in total

1.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Cationic microparticles: A potent delivery system for DNA vaccines.

Authors:  M Singh; M Briones; G Ott; D O'Hagan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 4.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

Authors:  M Briones; M Singh; M Ugozzoli; J Kazzaz; S Klakamp; G Ott; D O'Hagan
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

6.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Authors:  Lei Zhang; Ruy M Ribeiro; John R Mascola; Mark G Lewis; Gabriela Stiegler; Hermann Katinger; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.

Authors:  Zaza M Ndhlovu; Eleni Stampouloglou; Kevin Cesa; Orestes Mavrothalassitis; Donna Marie Alvino; Jonathan Z Li; Shannon Wilton; Daniel Karel; Alicja Piechocka-Trocha; Huabiao Chen; Florencia Pereyra; Bruce D Walker
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

9.  Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines.

Authors:  Ebony Gary; Margaret O'Connor; Marita Chakhtoura; Virginie Tardif; Ogan K Kumova; Delphine C Malherbe; William F Sutton; Nancy L Haigwood; Michele A Kutzler; Elias K Haddad
Journal:  Vaccine       Date:  2020-04-10       Impact factor: 3.641

Review 10.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.